

Paper

Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents

James Hotham, Rebecca Cannings-John, Laurence Moore, Jemma Hawkins, Chris Bonell, Matthew Hickman, Stanley Zammit, Lindsey A. Hines, Linda Adara, Julia Townson and James White

Background

Cannabis has been associated with poorer mental health, but little is known of the effect of synthetic cannabinoids or cannabidiol (often referred to as CBD).

Aims

To investigate associations of cannabis, synthetic cannabinoids and cannabidiol with mental health in adolescence.

Method

We conducted a cross-sectional analysis with 13- to 14-year-old adolescents across England and Wales in 2019–2020. Multilevel logistic regression was used to examine the association of lifetime use of cannabis, synthetic cannabinoids and cannabidiol with self-reported symptoms of probable depression, anxiety, conduct disorder and auditory hallucinations.

Results

Of the 6672 adolescents who participated, 5.2% reported using of cannabis, 1.9% reported using cannabidiol and 0.6% reported using synthetic cannabinoids. After correction for multiple testing, adolescents who had used these substances were significantly more likely to report a probable depressive, anxiety or conduct disorder, as well as auditory hallucinations, than those who had not. Adjustment for socioeconomic disadvantage had little effect on associations, but weekly tobacco use resulted in

marked attenuation of associations. The association of cannabis use with probable anxiety and depressive disorders was weaker in those who reported using cannabidiol than those who did not. There was little evidence of an interaction between synthetic cannabinoids and cannabidiol.

Conclusions

To our knowledge, this study provides the first general population evidence that synthetic cannabinoids and cannabidiol are associated with probable mental health disorders in adolescence. These associations require replication, ideally with prospective cohorts and stronger study designs.

Keywords

Anxiety or fear-related disorders; conduct disorders; depressive disorders; substance use disorders; psychotic disorders/schizophrenia.

Copyright and usage

© The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Globally, cannabis is the most widely used and internationally regulated illicit drug.¹ Cannabis use has been consistently associated with an increased risk of mental health disorders. The strongest evidence is found for psychosis,² with limited evidence for depression and anxiety.³ Delta-9-tetrahydrocannabinol (THC) is the most researched psychoactive cannabinoid in herbal cannabis.⁴ Experimental evidence suggests that the effects of THC on psychotomimetic symptoms, similar to those experienced with psychosis (e.g. hallucinations, delusions, paranoia), are dose-dependent.⁵ Far fewer studies have researched the effects of other cannabinoids. There has been research suggesting cannabis of a higher potency, defined as the ratio of cannabidiol (often referred to as CBD) to THC, is associated with an increased risk of psychosis and cannabis use disorder,⁶ and some evidence suggesting that cannabidiol attenuates psychotomimetic effects of THC,⁷ but little research into the effects of cannabidiol in isolation. The limited experimental evidence on cannabidiol suggests it may alleviate symptoms of psychosis and social anxiety.⁸ There is a comparable paucity of population-level research into the effects of synthetic cannabinoids. Although THC is a partial agonist with weak affinity for the CB1 receptor, synthetic cannabinoids are full agonists and generally have a higher affinity such that more potent effects might be expected. The limited case reports suggest synthetic cannabinoids can have profound acute effects in young people, including anxiety, paranoia, hallucinations, breathlessness and tachycardia.⁹

Legal status of cannabis, cannabidiol and synthetic cannabinoids

Cannabis use policy is liberalising in several jurisdictions. The use of the herbal cannabis and associated derived products containing THC is, however, illegal in the majority of the world.¹⁰ In contrast, synthetic cannabinoids often start as unregulated legal products, but after a period either become controlled (e.g. the USA's Synthetic Drug Abuse Prevention Act of 2012)¹¹ or come under blanket acts that ban products with psychoactive effects (e.g. the UK's Psychoactive Substances Act).¹² In contrast, cannabidiol is a legally marketed product in the USA and many European countries. In the USA in 2019, cannabidiol was one of the top ten selling herbal supplements in mainstream stores, increasing revenue by 872% from 2018, with total USA sales of close to \$36 million,¹³ and is often advertised as a natural over-the-counter remedy for mental health problems.¹⁴

Methodological limitations of previous research

Nearly all research to date has focused on the association between cannabis and mental health, with very few studies on use of synthetic cannabinoids and cannabidiol. Existing studies have also tended to be either small and thus likely lacking in statistical power, case reviews which might introduce sampling bias,⁹ or based on cannabinoids administered in a laboratory, which is unlikely to reflect how these drugs are used in the general

population.¹⁵ As far as we are aware, there have been no studies of the association between cannabis, synthetic cannabinoids and cannabidiol, and the risk of probable mental health disorders in a general adolescent population sample.

Aims

To address these limitations, we aimed to (a) describe the use of cannabis, synthetic cannabinoids and cannabidiol among a population of UK adolescents; (b) examine associations between the use of cannabis, synthetic cannabinoids and cannabidiol and symptoms from a range of mental health disorders; and (c) explore the extent to which cannabidiol modifies the association between cannabis and synthetic cannabinoids and probable disorders.

Method

Study population

These data arise from baseline assessments within a randomised controlled trial in England and Wales between September 2019 and March 2020.¹⁶ Schools were randomly sampled from the West of England and South Wales. Questionnaires were self-completed by year 9 students (aged 13–14 years) before random allocation. Fee-paying schools, schools for children only with learning difficulties and pupil referral units were excluded. Paper questionnaires were completed by students in classrooms under examination conditions. Further details are available elsewhere.¹⁶ Of 7077 eligible students, 6672 participated and completed the questionnaire (94.3% response). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures were approved by Cardiff University's School of Social Sciences Ethics Committee (approval number: SREC/3342; public trials' registry: ISRCTN72047541). Written informed consent was obtained from all participants and a process of opt-out consent was used with parents. This manuscript adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement reporting guidelines.¹⁷

Exposure

Participants were asked whether they have ever tried: 'cannabis (also called: marijuana, spliff, hash, skunk, grass, draw, dab, shatters)', 'CBD products (also called: cannabidiol, CBD oil)' and 'synthetic cannabinoids (these mimic the effect of cannabis; they are also called: spice, black mamba)'. Images were provided of each type of cannabis reduce misclassification of use (questions shown in the supplementary material available at <https://doi.org/10.1192/bjp.2023.91>). The images of cannabis were taken from a previously validated measure of cannabis potency,¹⁸ a stock image was used for cannabidiol and synthetic cannabinoid images were taken from the UK national drug education website (www.talktofrank.com).

Outcomes

Probable depressive disorder

Participants completed the 13-item Short Mood and Feelings Questionnaire, which assesses depressive symptoms over the past 2 weeks.¹⁹ We applied the validated cut-off point of ≥ 12 to indicate a disorder.¹⁹

Probable anxiety disorder

Participants completed the seven-item Generalised Anxiety Disorder-7 (GAD-7) screener, which assesses anxiety symptoms

over the past 2 weeks.²⁰ We applied the validated cut-off point of ≥ 10 , which is considered indicative of a disorder.²⁰

Probable conduct disorder

The Oregon Adolescent Depression Project Conduct Disorder Screener was completed by participants.²¹ It has six items asking whether participants have engaged in behaviours such as getting into fights in the past week. We applied the cut-off point of ≥ 9 as indicative of disorder.²¹

Auditory hallucinations

A binary measure for experience of an auditory hallucinations (0 indicating no hallucinations, 1 indicating hallucinations) was constructed from self-report data, using questions from the World Health Organization Composite International Diagnostic Interview.²² Young people who reported a hallucination were then asked about the distress caused by this experience (response options ranging from not to very distressing) and frequency (not at all to nearly every day/ daily). To increase the diagnostic relevance, we recoded responses into very distressing versus the other categories of distress, and into nearly every day/daily versus the other frequency categories.

Covariates

Gender identity was self-reported and categorised as boy, girl or a gender minority (transboy, transgirl, non-binary (neither male nor female), unsure/questioning, other, prefer not to say). Participants also reported their age, ethnicity, employment status of adults they lived with, free school meal entitlement and weekly smoking status (at least one cigarette a week). To describe the characteristics of users and non-users of each cannabinoid, we also assessed participants' consumption of a whole alcoholic drink in the past 30 days and the frequency of cannabis use over the past 12 months (never, monthly or less, weekly or more).

Statistical analysis

To describe the characteristics of young people who reported using each type of cannabis, we compared the demographic characteristics, exposure to socioeconomic disadvantage, weekly smoking status and use of alcohol in the past 30 days according to cannabis use, with univariable multilevel logistic regression (students nested within schools). The association between each type of cannabis and mental health was analysed using univariable and multivariable multilevel logistic regression (students nested within schools). Two separate multivariable models were performed for the association of exposure to cannabis, synthetic cannabinoids and cannabidiol with each outcome, to examine the potential confounding effects of (a) adjusting for gender identity and socioeconomic disadvantage (comprising living with no adults in part- or full-time employment and entitlement to free school meals), and (b) after additional adjustment for weekly smoking status. Subgroup analyses were conducted in participants reporting an auditory hallucination into whether use of cannabis, synthetic cannabinoids and cannabidiol were associated with being very distressed by hallucination(s) and hallucinating nearly every day or more. Interactions were then modelled between cannabidiol and both cannabis and synthetic cannabinoids when examining their associations with probable disorders, adjusting for gender identity, socioeconomic disadvantage and weekly smoking status. Results are presented as odds ratios with 95% confidence intervals. To reduce the risk of generating spurious findings resulting from multiple testing, the threshold for significance was Bonferroni-adjusted to $P < 0.001$ ($P = 0.05/42$). Sensitivity analyses were conducted after excluding participants

with any missing data and using cannabis frequency as the exposure variable, and examined the percentage overlap in reported cannabis, cannabidiol, synthetic cannabinoid and weekly smoking. Analyses were performed in Stata version 17.0 for Windows (StataCorp).

Missing data and imputation

Missing data per variable ranged from 1.0 to 9.5%. Missing data in all variables (exposures, outcomes and covariates) were addressed through multiple imputation, using chained equations. Each model included all variables, including the following auxiliary variables: age, ethnicity and alcohol consumption in the past 30 days. Estimates were obtained by pooling results across 20 imputed datasets according to Rubin rules, and assessment of Monte Carlo errors suggested that this was a suitable number of imputations.²³

Results

Of the 6672 participants, 5.2% (95% CI 4.6–5.7%) reported using cannabis, 1.9% (95% CI 1.6–2.3%) reported using cannabidiol and 0.6% (95% CI 0.4–0.7%) reported using synthetic cannabinoids (Table 1). Use of cannabis was more common in participants who identified as a gender minority than boy (12.3 v. 5.1%) or girl (4.8%), were entitled to free school meals (9.6 v. 4.6%), lived with no employed adults (11.3 v. 4.8%), were weekly smokers (79.4 v. 4.0%) and had consumed alcohol in the past 30 days (12.0 v. 0.9%). Use of cannabidiol was more common in those who were entitled to free school meals (3.9 v. 1.6%), lived with no employed adults (3.6 v. 1.8%), were weekly smokers (33.3 v. 1.8%) and had consumed alcohol in the past 30 days (4.2 v. 0.5%). The characteristics of synthetic cannabinoid users were very similar to those for cannabis and cannabidiol. There was a stepped association between cannabidiol and cannabis use in the past 12 months (never, 0.8%; monthly or less, 18.5%; weekly or more, 49.2%) and reported synthetic cannabinoids use (never, 0.1%; monthly or less, 4.7%; weekly or more, 26.7%) (Table 1).

The prevalence was 22.7% for probable depressive disorder (95% CI 21.6–23.7%), 19.9% for anxiety disorder (95% CI 18.8–20.9%), 22.1% for conduct disorder (95% CI 21.1–23.1%) and 17.7% (95% CI 16.6–18.8%) for auditory hallucinations. There was a significant unadjusted association between the use of cannabis and probable depressive disorder (odds ratio 3.28, 95% CI 2.58–4.10), anxiety disorder (odds ratio 2.94, 95% CI 2.32–3.72), conduct disorder (odds ratio 8.17, 95% CI 6.35–10.51) and auditory hallucinations (odds ratio 3.10, 95% CI 2.35–4.10) (Table 2). There was also a significant unadjusted association between the use of cannabidiol and probable depressive disorder (odds ratio 3.51, 95% CI 2.40–5.12), anxiety disorder (odds ratio 3.09, 95% CI 2.11–4.53), conduct disorder (odds ratio 8.21, 95% CI 5.38–12.53) and auditory hallucinations (odds ratio 4.65, 95% CI 3.02–7.16). Those who reported using synthetic cannabinoids reported more symptoms consistent with a probable depressive disorder (odds ratio 6.44, 95% CI 3.07–13.52), anxiety disorder (odds ratio 6.24, 95% CI 3.05–12.79), conduct disorder (odds ratio 29.52, 95% CI 10.32–84.42) and auditory hallucinations (odds ratio 12.22, 95% CI 4.29–34.84) than those who had not used. There was little evidence of attenuation of these associations after adjustment for sociodemographic factors. Associations were markedly reduced after the addition of weekly smoking, but participants using any of these cannabinoids remained more than twice as likely to report a probable disorder or an auditory hallucination compared with their peers who reported no use (Table 2).

Among students who reported hallucinations, there was an unadjusted association between the use of cannabis and being

very distressed by the hallucination (odds ratio 2.66, 95% CI 1.52–4.65). There was weaker evidence of an association for use of cannabidiol (odds ratio 1.83, 95% CI 0.74–4.52) or synthetic cannabinoids (odds ratio 2.20, 95% CI 0.58–8.33). There was evidence that hallucinating nearly every day was associated with use of cannabidiol (odds ratio 2.15, 95% CI 1.06–4.38) and synthetic cannabinoids (odds ratio 2.88, 95% CI 0.94–8.83), but there was weaker evidence of an association for cannabis use (adjusted odds ratio 1.30, 95% CI 0.71–2.37). Associations were again attenuated after adjusting for weekly smoking (Supplementary Table 1).

There was an interaction between cannabis and cannabidiol use for probable depressive and anxiety disorders. Evidence for an association between cannabis and probable depressive disorder was stronger in those who did not use cannabidiol (adjusted odds ratio 2.77, 95% CI 2.05–3.75) than those who did (adjusted odds ratio 0.66, 95% CI 0.26–1.70; $P_{\text{interaction}} = 0.001$). This pattern was also observed in the association between cannabis and probable anxiety disorders (cannabis users: adjusted odds ratio 2.33, 95% CI 1.71–3.18; cannabis non-users: adjusted odds ratio 0.83, 95% CI 0.31–2.18; $P_{\text{interaction}} = 0.001$). To explore these interactions, we examined the frequency of cannabis use by cannabidiol use. There was evidence that cannabis use was more frequent in cannabidiol users (never, 40.9%; monthly, 32.7%; weekly, 26.4%) than non-users (never, 96.7%; monthly, 2.8%; weekly, 0.5%).

There was, however, little evidence of an interaction between cannabis and cannabidiol use for symptoms of conduct disorders ($P_{\text{interaction}} = 0.07$), auditory hallucinations ($P_{\text{interaction}} = 0.22$), nor synthetic cannabinoid and cannabidiol use in associations with probable disorders (depressive disorder: $P_{\text{interaction}} = 0.48$; anxiety disorder: $P_{\text{interaction}} = 0.27$; conduct disorder: $P_{\text{interaction}} = 0.99$; auditory hallucinations: $P_{\text{interaction}} = 0.81$).

Sensitivity analysis conducted in the data-sets where there was no missing data showed that the confidence intervals for estimates overlapped with those from the main results using imputed data, indicating there were no meaningful differences (Supplementary Tables 2 and 3). There was a stepwise association between cannabis frequency and outcomes. Adjustment for weekly smoking status attenuated these associations, particularly for those who used cannabis on a weekly basis or more frequently (Supplementary Table 4). There was a greater overlap between weekly smoking with cannabis than cannabidiol or synthetic cannabinoid use (Supplementary Table 5).

Discussion

Main findings

In a general population sample of 13- to 14-year-olds in the UK, individuals using cannabis, synthetic cannabinoids or cannabidiol (compared with those who did not) were more likely to report symptoms consistent with a probable depressive disorder, anxiety disorder, conduct disorder or auditory hallucinations. There was some evidence that the strength of associations varied by substance, with the largest associations for synthetic cannabinoids, although confidence intervals for all overlapped. Adjusting for tobacco use attenuated associations, but evidence of these associations was still present. These results are the first to provide a profile of young adolescents who use cannabidiol and synthetic cannabinoids, indicating that, as for cannabis, use is more common among young people who live with parents with a relatively low income, are unemployed, report being a weekly smoker or have used alcohol in the past 30 days. Around 40% of the young people who had used cannabidiol had never used cannabis, whereas around half of those using synthetic cannabinoids had used cannabis weekly or more often over the previous year. As far as we are aware, this is the first study to

Table 1 Association between type of cannabis and participant characteristics (N = 6672)

Characteristic	Cannabis, %			Cannabidiol, %			Synthetic cannabinoids, %		
	Never (n = 6326) ^a	Used (n = 346)	P-value ^b	Never (n = 6545)	Used (n = 127)	P-value ^b	Never (n = 6632)	Used (n = 40)	P-value ^b
Gender identity									
Boy	94.9	5.1		97.9	2.1		99.4	0.6	
Girl	95.2	4.8	0.56	98.3	1.7	0.22	99.5	0.5	0.85
Gender minority ^c	87.7	12.3	<0.001	96.7	3.3	0.29	98.6	1.4	0.22
Ethnicity									
White	94.7	5.3		98.1	1.9		99.5	0.5	
Black, Asian and minority ethnic	96.1	3.9	0.17	97.2	2.8	0.14	98.3	1.7	0.001
Entitled to free school meals									
Yes	90.5	9.5		96.1	3.9		98.6	1.3	
No	95.4	4.6	<0.001	98.4	1.6	<0.001	99.5	0.5	0.006
Do not know	94.5	5.5	0.33	97.6	2.4	0.10	99.4	0.6	0.76
Parental unemployment									
Unemployed	88.7	11.3		96.4	3.6		98.5	1.4	
Employed	95.2	4.8	<0.001	98.2	1.8	0.02	99.5	0.5	0.03
Weekly smoking									
Not smoked	96.0	4.0		98.6	1.4		99.7	0.3	
Smoked	20.6	79.4	<0.001	66.7	33.3	<0.001	85.2	14.8	<0.001
Alcohol in past 30 days									
Not consumed	99.1	0.9		99.5	0.5		99.9	0.1	
Consumed	88.0	12.0	<0.001	95.7	4.2	<0.001	98.7	1.3	0.001
12-month frequency of cannabis ^d									
Not used		14.0		99.2	0.8		99.9	0.1	
Monthly or less		65.9		81.5	18.5	<0.001	95.3	4.7	<0.001
Weekly or more		20.0		50.8	49.2	<0.001	73.3	26.7	<0.001

a. All numbers estimated from imputed proportions.
b. Determined by logistic regression.
c. Gender minority comprised transboy, transgirl, non-binary (neither male or female), unsure/questioning and other.
d. No observations on frequency for those who did not use.

examine the link between using different cannabinoids and a range of mental health outcomes in adolescence.

Comparison with previous findings

To our knowledge, the present study gives the first profiles for both cannabidiol and synthetic cannabinoid users in young adolescents. A survey of university students in the USA found that synthetic cannabinoid users did not differ greatly from cannabis

users.²⁴ Synthetic cannabinoid users were slightly younger than abstainers and more likely to be of non-Hispanic White ethnicity. A household survey of German people aged over 14 years found that having ever used cannabidiol was associated with higher education level, urban living, tobacco use and e-cigarette use.²⁵ We replicated the link for cannabidiol and synthetic cannabinoid use with the use of cannabis and tobacco, but found that use of all cannabinoids was associated with greater exposure to household socioeconomic deprivation.

Table 2 Odds ratio for association between lifetime cannabis, cannabidiol and synthetic cannabinoid use with probable depressive disorder, generalised anxiety disorder, conduct disorder and auditory hallucinations (N = 6672)

Exposure variable	Odds ratio (95% CI)		
	Unadjusted	Adjusted for sociodemographic factors ^a	Additionally adjusted for weekly smoking
Probable depressive disorder			
Cannabis	3.25 (2.58–4.10)***	3.48 (2.72–4.46)***	2.73 (2.07–3.60)***
Cannabidiol	3.51 (2.40–5.12)***	4.06 (2.71–6.07)***	2.89 (1.87–4.44)***
Synthetic cannabinoids	6.44 (3.07–13.52)***	7.28 (3.36–15.78)***	4.18 (1.80–9.71)
Probable generalised anxiety disorder			
Cannabis	2.94 (2.32–3.72)***	3.00 (2.34–3.85)***	2.35 (1.76–3.13)***
Cannabidiol	3.09 (2.11–4.53)***	3.42 (2.29–5.11)***	2.42 (1.57–3.76)***
Synthetic cannabinoids	6.24 (3.05–12.79)***	6.80 (3.18–14.54)***	4.03 (1.78–9.13)
Probable conduct disorder			
Cannabis	8.17 (6.35–10.51)***	7.88 (6.11–10.16)***	5.60 (4.26–7.35)***
Cannabidiol	8.21 (5.38–12.53)***	7.85 (5.12–12.02)***	5.25 (3.31–8.35)***
Synthetic cannabinoids	29.52 (10.32–84.42)***	28.12 (9.78–80.88)***	16.47 (5.43–49.97)***
Auditory hallucinations ^b			
Cannabis	3.10 (2.35–4.10)***	2.84 (2.13–3.79)***	2.25 (1.62–3.11)***
Cannabidiol	4.65 (3.02–7.16)***	4.57 (2.94–7.12)***	3.44 (2.23–5.55)***
Synthetic cannabinoids	12.22 (4.29–34.84)***	11.00 (3.76–32.19)***	7.08 (2.30–21.85)***

Probable depressive disorder defined as scoring ≥ 12 on the Short Mood and Feelings Questionnaire; probable generalised anxiety disorder defined as scoring ≥ 10 on the Generalised Anxiety Disorder-7 screener; probable conduct disorder defined as scoring ≥ 9 on the Oregon Adolescent Depression Project Conduct Disorder Screener.
a. Sociodemographic factors comprised gender identity, free school meal entitlement and living with an employed parent.
b. Analytical n = 5105 as it excludes students who responded that they preferred not to say or did not know whether they had hallucinated.
*** Statistically significant under a Bonferroni-corrected $P < 0.001$ for 42 comparisons.

Cannabis use was associated with all of the mental health outcomes assessed. These findings support other reports of cannabis use in adolescents being a risk factor for developing mental illness in early adulthood.³ We have characterised the attenuation after adjusting for weekly smoking, because of confounding, as the majority of studies suggest the initiation of smoking tobacco tends to precede cannabis use.²⁵ Having said this, recent research indicates the age of tobacco smoking initiation has increased among youth in the USA,²⁶ whereas the initiation age for cannabis has remained stable.²⁷ There is also data from the UK suggesting that cannabis use has increased over time among 11- to 16-year-olds, whereas tobacco use stayed the same.²⁸ This suggests that for some young people, it is possible that regular smoking developed secondary to cannabis use, and that this therefore acted as a mediator rather than a confounding factor, if smoking increases the risk of these disorders. This could mean that this adjusted analysis might underestimate the real associations between cannabis use and mental health outcomes.

Synthetic cannabinoids had large (but imprecise) associations with mental health outcomes. We found fewer than 1% of students had used synthetic cannabinoids. We could not find any other estimates of synthetic cannabinoid prevalence in adolescence. One convenience sample of USA undergraduates found 7.9% reported ever using synthetic cannabinoids, and that use was associated with considering attending an emergency department for anxiety, depression or hallucinations.²⁴ Another USA registry study of 107 adolescents presenting to emergency departments found synthetic cannabinoid use was associated with a higher occurrence of acute neuropsychiatric symptoms (e.g. coma, central nervous system depression) than cannabis, and effects were stronger where patients had used other drugs alongside cannabinoids.²⁹

Cannabidiol was associated with an increased risk of probable depressive, anxiety and conduct disorders and auditory hallucinations. Randomised and non-randomised controlled trials administering cannabidiol have found improvements in symptoms of psychosis and in patients with social anxiety.⁸ One systematic review of 20 observational studies suggested that cannabis with a higher cannabidiol/THC concentration may have less of an effect on psychosis and cannabis use disorder than cannabis with a lower cannabidiol/THC ratio.⁶ Laboratory studies investigating the effect of cannabidiol consumed before THC or cannabis have had mixed results. One adult study found that people who took cannabidiol before being given THC were less likely to experience clinically significant psychotic symptoms or paranoia,¹⁵ but other studies with adolescents have not replicated this effect.³⁰

In the present study, we found exploratory evidence of an interaction on a multiplicative scale between cannabidiol use and cannabis use, such that the association between cannabis and depression and anxiety was weaker in those who had also used cannabidiol than those who had not. Although these findings are potentially consistent with cannabidiol ameliorating the effects of cannabis on depression and anxiety, there are alternative explanations. It could be that cannabidiol users use cannabis less frequently, have had less cumulative use of cannabis or select cannabis with a higher cannabidiol/THC ratio, compared with those who do not use cannabidiol. We found the frequency of cannabis use was higher in cannabidiol users than non-users, suggesting there is limited support for that explanation. For these reasons, and as we do not know whether individuals ever used cannabidiol and cannabis at the same time, this finding has to be regarded as highly speculative.

Strengths and limitations

One of the strengths of our study lies in the use of a large sample of adolescents, as both cannabidiol and synthetic cannabinoid have a

relatively low prevalence. Another strength is the use of pictorial aids for the different types of cannabis to reduce the chance of misclassification, and multiple validated measures of probable disorders covering a range of symptoms previously linked with cannabis use.³ We had a high response rate to our survey and a low amount of missing data for each variable. To account for the missing data, we used multiple imputation to maximise the plausibility of the missing at random assumption. Results were comparable when using the data-sets with missing and imputed data, increasing confidence in the findings. Bias attributable to non-ignorable missing data cannot, however, be ruled out completely.

The cross-sectional design of the study means we cannot establish whether the associations reported are causal. Reverse causality is a tenable explanation for the associations reported, where young people with existing mental health problems choose to use cannabis, synthetic cannabinoids or cannabidiol because they believe it will improve their symptoms. In the case of cannabidiol, this may be because cannabidiol is advertised as a natural over-the-counter remedy for mental health problems.¹⁴ We found an association between use of each cannabinoid and conduct disorder, but it is unclear what mechanism underpins this association. An alternative to a causal explanation is that these associations are brought about by confounding, whereby both cannabinoid use and probable mental health disorder share common antecedents, such as exposure to adverse childhood experiences.³¹ The questions on the use of three cannabinoids did not ask whether use was concurrent. This limits the inferences that can be drawn from the interactions showing that cannabidiol moderated the association between cannabis use and anxiety and depressive symptoms, particularly given the limitation around mechanistic understanding from most patterns of interaction.³² It is possible that young people who used both cannabis and cannabidiol had a lower profile of risk factors for mental disorder than those who solely used cannabis. We did not assess the frequency of cannabidiol and synthetic cannabinoid use, limiting inferences that could have been drawn on the extent of exposure. The exclusion of fee-paying schools would have reduced the variability in the assessment of socioeconomic disadvantage and, potentially, the confounding effect of socioeconomic disadvantage on associations.

Implications

Using data from a general population sample in the UK, we found the use of cannabis, synthetic cannabinoids and cannabidiol was associated with an increased risk of three probable mental health disorders. General population studies are useful in estimating associations at the population level, and can be crucial for informing policy makers and clinical service providers. There is a need for larger trials into the effectiveness and safety of cannabidiol as a treatment for depression, anxiety and psychosis, and greater consideration of how cannabidiol is marketed given the paucity of evidence of benefit to mental health. Our findings signal to clinicians, educators and policy makers that there is a need for education on the uncertainty in the evidence of benefit for cannabidiol and additional research, ideally with longitudinal data into the link between synthetic cannabinoid use and probable mental health disorders in young people.

James Hotham , MRCPsych, Old Age Psychiatry, Penn Hospital, Black Country Healthcare NHS Foundation Trust, UK; **Rebecca Cannings-John**, PhD, Centre for Trials Research, School of Medicine, Cardiff University, UK; **Laurence Moore**, PhD, MRC/CSO Social and Public Health Sciences Unit, Institute of Health and Wellbeing, University of Glasgow, UK; **Jemma Hawkins**, PhD, Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer), School of Social Sciences, Cardiff University, UK; **Chris Bonell**, PhD, Department of Public Health, Environment and Society, London School of Hygiene & Tropical Medicine, UK; **Matthew Hickman**, PhD, Department of Population Health Sciences, University of Bristol, UK; **Stanley Zammit**, PhD, Department of Population Health Sciences, University

of Bristol, UK; and MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK; **Lindsey A. Hines**, PhD, Department of Population Health Sciences, University of Bristol, UK; **Linda Adara**, PhD, Centre for Trials Research, School of Medicine, Cardiff University, UK; **Julia Townson**, PhD, Centre for Trials Research, School of Medicine, Cardiff University, UK; **James White**, PhD, Centre for Trials Research, School of Medicine, Cardiff University, UK; and Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer), School of Social Sciences, Cardiff University, UK

Correspondence: James White. Email: whitej11@cardiff.ac.uk

First received 9 Feb 2023, final revision 17 May 2023, accepted 30 May 2023

Supplementary material

To view supplementary material for this article, please visit <https://doi.org/10.1192/bjp.2023.91>

Data availability

The data that support the findings of this study are openly available at <https://doi.org/10.17035/d.2023.0244798057>.

Author contributions

J.W., S.Z. and L.A.H. conceived the concept. J.W., R.C.-J., L.M., J. Hawkins, C.B., M.H. and J.T. secured the funding. L.A., J.W., R.C.-J., L.M., J. Hawkins, C.B., M.H. and J.T. designed the protocol. L.A. and J.T. recruited participants. J.W. analysed the data. J. Hawkins, J.Hotham, S.Z., L.A.H., J.W., R.C.-J., L.M., C.B., M.H. and J.T. interpreted the findings. J. Hotham created the first draft of the manuscript. S.Z., L.A.H., J.W., R.C.-J., L.M., J. Hawkins, C.B., M.H., J.T., J. Hotham and L.A. critically revised and approved the manuscript. All authors had final responsibility for the decision to submit for publication. J.W. and J. Hotham are guarantors of the manuscript.

Funding

This work was supported by the National Institute of Health Research (NIHR) Public Health Research programme (grant number NIHR PHR 17/97/02) at the Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer), a UK Clinical Research Collaboration Public Health Research Centre of Excellence. Joint funding was received from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the Welsh Government and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration (MR/K0232331/1); and since April 2020, the Welsh Government through Health and Care Research Wales, the Medical Research Council (MC_UU_00022/1) and the Chief Scientist Office (SPHSU16). S.Z. is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. L.A.H. is funded by the Wellcome Trust (grant number 209158/Z/17/Z). For the purpose of open access, the authors have applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care. The funder had no role in the design, or conduct of the study; collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.

Declarations of interest

None.

References

- 1 United Nations Office on Drugs and Crime (UNODC). *World Drug Report 2016*. UNODC, 2016 (https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_2016_web.pdf).
- 2 Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* 2007; **370**(9584): 319–28.
- 3 Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. *JAMA Psychiatry* 2019; **76**(4): 426–34.
- 4 Sideli L, Quigley H, La Cascia C, Murray RM. Cannabis use and the risk for psychosis and affective disorders. *J Dual Diagn* 2020; **16**(1): 22–42.
- 5 D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology* 2004; **29**(8): 1558–72.
- 6 Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. *Lancet Psychiatry* 2022; **9**(9): 736–50.
- 7 Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. *Transl Psychiatry* 2018; **8**(1): 181.
- 8 Khan R, Naveed S, Mian N, Fida A, Raafey MA, Aedma KK. The therapeutic role of cannabidiol in mental health: a systematic review. *J Cannabis Res* 2020; **2**(1): 2.
- 9 Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. *J Spec Pediatr Nurs* 2014; **19**(2): 119–26.
- 10 Hall W, Lynskey M. Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. *Lancet Psychiatry* 2016; **3**(9): 900–6.
- 11 US Congress. *Synthetic Drug Abuse Prevention Act of 2012*. Library of Congress, 2012 (<https://www.congress.gov/bills/112th-congress/senate-bill/3190/text>).
- 12 UK Government. *Psychoactive Substances Act 2016*. The Stationery Office, 2016 (<https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted>).
- 13 Smith T, May G, Eckl V, Morton Reynolds C. *New Market Data: Herbal Supplement Sales Soar, CBD Leads the Way*. Therapeutic Research Center, 2020 (<https://naturalmedicines.therapeuticresearch.com/news/news-items/2020/october/new-market-data-herbal-supplement-sales-soar-cbd-leads-the-way.aspx#:~:text=October%202020-,New%20Market%20Data%3A%20Herbal%20Supplement%20Sales%20Soar%2C%20CBD%20Leads%20the,in%20the%20past%20couple%20years>).
- 14 Zenone MA, Snyder J, Crooks V. Selling cannabidiol products in Canada: a framing analysis of advertising claims by online retailers. *BMC Public Health* 2021; **21**: 1285.
- 15 Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. *J Psychopharmacol* 2013; **27**(1): 19–27.
- 16 White J, Hawkins J, Townson Julia, Smallman K, Cannings-John R, Parrott S, et al. *A Multicentre Cluster Randomised Controlled Trial to Evaluate the Effectiveness and Cost-Effectiveness of a School-Based Peer-Led Drug Prevention Intervention (The FRANK Friends Study)*. National Institute for Health and Care Research, 2019 (<https://www.journalslibrary.nihr.ac.uk/programmes/phr/179702/#/>).
- 17 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; **61**(4): 344–9.
- 18 Forti MD, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry* 2019; **6**(5): 427–36.
- 19 Ancold A, Stephen C. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. *Int J Methods Psychiatr Res* 1995; **5**(4): 237–49.
- 20 Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006; **166**(10): 1092–7.
- 21 Lewinsohn PM, Rohde P, Farrington DP. The OADP-CDS: a brief screener for adolescent conduct disorder. *J Am Acad Child Adolesc Psychiatry* 2000; **39**(7): 888–95.
- 22 Kessler RC, Üstün TB. The world mental health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int J Methods Psychiatr Res* 2004; **13**(2): 93–121.
- 23 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011; **30**(4): 377–99.
- 24 Mathews EM, Jeffries E, Hsieh C, Jones G, Buckner JD. Synthetic cannabinoid use among college students. *Addict Behav* 2019; **93**: 219–24.
- 25 Alayli AFG, Kotz D, Kastaun S. Recreational cannabidiol: awareness, prevalence of use, and associated factors in a representative sample of the German population. *Subst Use Misuse* 2022; **57**(9): 1417–24.
- 26 Keyes KM, Rutherford C, Miech R. Historical trends in the grade of onset and sequence of cigarette, alcohol, and marijuana use among adolescents from 1976–2016: implications for “gateway” patterns in adolescence. *Drug Alcohol Depend* 2019; **194**: 51–8.
- 27 Terry-McElrath YM, O'Malley PM, Johnston LD. Changes in the order of cigarette and Marijuana initiation and associations with cigarette use, nicotine

vaping, and marijuana use: U.S. 12th grade students, 2000–2019. *Prev Sci* 2020; **21**(7): 960–71.

- 28 Page N, Hallingberg B, Brown R, Lowthian E, Hewitt G, Murphy S, et al. Change over time in adolescent smoking, cannabis use and their association: findings from the school health research network in Wales. *J Public Health* 2020; **43**(4): e620–8.
- 29 Anderson SAR, Oprescu AM, Calello DP, Monte A, Dayan PS, Hurd YL, et al. Neuropsychiatric sequelae in adolescents with acute synthetic cannabinoid toxicity. *Pediatrics* 2019; **144**(2): e20182690.
- 30 Mokrysz C, Shaban NDC, Freeman TP, Lawn W, Pope RA, Hindocha C, et al. Acute effects of cannabis on speech illusions and psychotic-like symptoms:

two studies testing the moderating effects of cannabidiol and adolescence. *Psychol Med* 2021; **51**(12): 2134–42.

- 31 Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. *Lancet Public Health* 2017; **2**(8): e356–66.
- 32 Zammit S, Lewis G, Dalman C, Allebeck P. Examining interactions between risk factors for psychosis. *Br J Psychiatry* 2010; **197**(3): 207–11.



Poem

The Accounts

Giles Nicholas James Constable 

I hear the accounts.
Voices which suggest life is already done,
that coming here is coming to no place at all.
Just somewhere not there, not then.
No profit, only loss.

The interpreter sometimes weeps,
will not tell what has been said,
something too particular, too infernal,
done by fire, by water,
inundating memory,
language left insufficient, ravaged.

I sit behind my pad in my comfortable shoes,
my professional pose, ensconced in familiarity.

What chance we should meet,
that such distances have led us to share this space
where I listen, would bear witness.
Instead find myself a migrant visitor
to catastrophe. Dark tourist.

Today he showed me a photograph.
His two girls in uniform for school
holding up certificates, brimful with pride.
His shadow was cast onto the wall of their home,
onto the bricks which, when the missile hit,
soon after buried them.

I wake in the morning at four,
fugitive from some miscellaneous grief.
The room reassembles into the banality of my peace.
Listen to the house,
the still of my wife asleep,
my daughter as she coughs upstairs.
My great assets, my fortune.

And my nightmares,
which I may forget with ease,
are seldom and commonplace.

© The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists.

The British Journal of Psychiatry (2023)
223, 484. doi: 10.1192/bjp.2023.59